RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$56.45
0.02 (0.04%)
▲
5d:
-0.83%
30d:
+3.54%
90d:
+17.85%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RPRX trades at premium valuation expecting 5.1% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: RPRX trades at premium valuation expecting 5.1% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.92
Based on 5.4% avg growth
INTRINSIC VALUE TODAY
$39.07
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $56.45, which is considered slightly high relative to its 30-day fair value range of $54.19 to $57.04. From a valuation perspective, the stock is trading at a premium (Forward PE: 10.2) compared to its historical average (8.7). At these levels, the market is pricing in 5.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $55.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is currently testing key support at $55.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$54.19 -
$57.04
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
59.5%
Protect Your Profits
Holding RPRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($59.25)
- NEUTRAL: Trading at premium valuation - market expects 5.1% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$54.19 -
$57.04
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$55.34
Resistance Level
$58.84
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.15
Wall Street Target
$59.25
(+5.0%)
Revenue Growth (YoY)
11.0%
Earnings Growth (YoY)
23.2%
Profit Margin
33.9%
Valuation Premium vs History
+5.1% premium
PE vs Historical
10.2 vs 8.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.1%
(market-implied from PE analysis)
1-Year Target
$59.33
(+5%)
2-Year Target
$62.35
(+11%)
3-Year Target
$65.53
(+16%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$56.17
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 6.8%)
$147.41
(+161%)
Base:
(SPY PE: 10.2, Growth: 6.8%)
$68.70
(+22%)
Bear:
(PE: 8.6, Growth: 6.8%)
$58.40
(+3%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (30x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 29.70 | Current EPS (TTM): $1.90
Bull Case
$124.15
(+120%)
Analyst growth 100.0%, PE expands to 32.7
Base Case
$112.86
(+100%)
Market implied 100.0%, PE stable at 29.7
Bear Case
$38.37
(-32%)
Severe decline -20.0%, PE contracts to 25.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 3:58 AM ET
Data refreshes hourly during market hours. Next update: 4:58 AM
Data refreshes hourly during market hours. Next update: 4:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Terrance P Coyne
SELL
34791 shares
2026-04-01
Terrance P Coyne
SELL
34791 shares
2026-03-23
Terrance P Coyne
SELL
34791 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
